JP2020519230A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519230A5
JP2020519230A5 JP2018564966A JP2018564966A JP2020519230A5 JP 2020519230 A5 JP2020519230 A5 JP 2020519230A5 JP 2018564966 A JP2018564966 A JP 2018564966A JP 2018564966 A JP2018564966 A JP 2018564966A JP 2020519230 A5 JP2020519230 A5 JP 2020519230A5
Authority
JP
Japan
Prior art keywords
fusion protein
protein according
sequence
peptide
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018564966A
Other languages
English (en)
Japanese (ja)
Other versions
JP7161940B2 (ja
JP2020519230A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/032018 external-priority patent/WO2018209052A1/en
Publication of JP2020519230A publication Critical patent/JP2020519230A/ja
Publication of JP2020519230A5 publication Critical patent/JP2020519230A5/ja
Application granted granted Critical
Publication of JP7161940B2 publication Critical patent/JP7161940B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018564966A 2017-05-10 2018-05-10 がんの治療のための、補体不活性化に耐性のエンベロープウイルス Active JP7161940B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762504120P 2017-05-10 2017-05-10
US62/504,120 2017-05-10
PCT/US2018/032018 WO2018209052A1 (en) 2017-05-10 2018-05-10 Enveloped virus resistant to complement inactivation for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2020519230A JP2020519230A (ja) 2020-07-02
JP2020519230A5 true JP2020519230A5 (cg-RX-API-DMAC10.html) 2021-05-20
JP7161940B2 JP7161940B2 (ja) 2022-10-27

Family

ID=64105722

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018564966A Active JP7161940B2 (ja) 2017-05-10 2018-05-10 がんの治療のための、補体不活性化に耐性のエンベロープウイルス

Country Status (13)

Country Link
US (2) US11274141B2 (cg-RX-API-DMAC10.html)
EP (1) EP3621635A4 (cg-RX-API-DMAC10.html)
JP (1) JP7161940B2 (cg-RX-API-DMAC10.html)
KR (3) KR102839445B1 (cg-RX-API-DMAC10.html)
CN (3) CN121343934A (cg-RX-API-DMAC10.html)
AU (1) AU2018265258B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018075281A2 (cg-RX-API-DMAC10.html)
CA (1) CA3026892A1 (cg-RX-API-DMAC10.html)
IL (1) IL263979B2 (cg-RX-API-DMAC10.html)
MX (1) MX2018015599A (cg-RX-API-DMAC10.html)
NZ (1) NZ748798A (cg-RX-API-DMAC10.html)
WO (1) WO2018209052A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201808040B (cg-RX-API-DMAC10.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
CN112759654A (zh) * 2019-11-06 2021-05-07 深圳普菲科生命科技有限公司 一种病毒囊膜蛋白装配系统及其方法和应用
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4299729A4 (en) * 2021-02-26 2025-06-11 SillaJen, Inc. ONCOLYTIC VIRUS AND USE THEREOF
CN113736810B (zh) * 2021-09-08 2024-05-24 苏州因特药物研发有限公司 构建体、载体、蛋白、细胞、制备方法、产品及应用
KR102983542B1 (ko) * 2022-06-29 2026-06-30 신라젠(주) Cd55 및 cd59를 동시 발현하는 항암 바이러스
KR20240035360A (ko) * 2022-09-07 2024-03-15 신라젠(주) 항암 바이러스의 신규 용도

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374548A (en) * 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
ES2310580T3 (es) 1993-04-30 2009-01-16 Wellstat Biologics Corporation Composiciones purificadas del virus de la enfermedad de newcastle.
JPH10313865A (ja) * 1997-05-15 1998-12-02 Deinabetsuku Kenkyusho:Kk ヒト補体制御因子が呈示されたベクター
JP2002509695A (ja) * 1997-11-21 2002-04-02 ゲセルシャフト フュア バイオテクノロギッシェフォーシュング エムベーハー(ゲーベーエフ) 一本鎖dna又は二本鎖dna、コード化融合タンパク質,ウイルス,パッケージング細胞及びこれらの使用ヒト補体システムによる不活化に耐えるウイルスの開発
IL136905A0 (en) 1997-12-22 2001-06-14 Univ Tennessee Res Corp Recombinant rhabdovirus containing a heterologous fusion protein
CA2324284A1 (en) * 1998-04-02 1999-10-14 Rigel Pharmaceuticals, Inc. Peptides causing formation of compact structures
CN1477964A (zh) 1999-04-15 2004-02-25 应用病毒治疗肿瘤
CN100594037C (zh) 2002-11-15 2010-03-17 Musc研究发展基金会 通过补体受体2定向的补体调节剂
ATE478965T1 (de) * 2004-07-21 2010-09-15 Dana Farber Cancer Inst Inc Lentivirusvektoren und deren verwendung
JP5050198B2 (ja) * 2006-09-05 2012-10-17 国立大学法人大阪大学 ヒト補体制御因子発現遺伝子およびその利用
US20100120628A1 (en) * 2007-02-06 2010-05-13 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
MX2009009200A (es) 2007-03-01 2009-10-28 Advanced Vision Therapies Inc Tratamiento de enfermedades caracterizadas por la inflamacion.
US8877896B2 (en) 2008-02-15 2014-11-04 Tufts University Compositions, methods and kits for modeling, diagnosing, and treating complement disorders
JP2014516517A (ja) 2011-04-29 2014-07-17 キージーン・エン・フェー グリホサート耐性強化
SG194780A1 (en) 2011-05-05 2013-12-30 Wellstat Immunotherapeutics Llc Complement factor b analogs and their uses
BR112014013205A2 (pt) * 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
SG10202109752XA (en) * 2014-04-07 2021-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
SG11201708257UA (en) 2015-04-06 2017-11-29 Subdomain Llc De novo binding domain containing polypeptides and uses thereof
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
AU2016274989A1 (en) 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
CN109415706A (zh) 2016-05-19 2019-03-01 图恩斯通有限合伙公司 假型化的溶瘤弹状病毒及其在组合治疗中的应用

Similar Documents

Publication Publication Date Title
JP7250878B2 (ja) 新規多価ナノ粒子に基づくワクチン
ES2307550T3 (es) Di-u oligomero de un di-, tri-,tetra- o pentametro de proteinas de fusion recombinantes.
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
JP2019514373A5 (cg-RX-API-DMAC10.html)
JP7161940B2 (ja) がんの治療のための、補体不活性化に耐性のエンベロープウイルス
CN104342453A (zh) 含基因工程抗体基因表达盒的微环dna重组母质粒、含该表达盒的微环dna及应用
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa
JP2010501191A5 (cg-RX-API-DMAC10.html)
HRP20221531T1 (hr) Pripravci faktora viii i postupci dobivanja i korištenja istih
KR20190056382A (ko) 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
JP2014073123A (ja) パラミクソウイルス科(Paramyxoviridae)ファミリーのウイルスのNタンパク質−対象タンパク質の融合タンパク質
CN112135902A (zh) 癌症疗法
CN105143251B (zh) 流感核蛋白疫苗
JP2019530441A5 (cg-RX-API-DMAC10.html)
RU2008138536A (ru) Химерные вакцинные антигены против вируса классической чумы свиней
JP2013529178A5 (cg-RX-API-DMAC10.html)
JP2016520534A5 (cg-RX-API-DMAC10.html)
WO2017041739A1 (zh) 改造的白介素12及其在制备治疗肿瘤药物中的用途
CA2991213A1 (en) Recombinant virus like particles using bovine immunodeficiency virus gag protein
KR101525180B1 (ko) 인플루엔자 바이러스 항원의 세포표면 발현벡터 및 이에 의해 형질전환된 미생물
US20250064873A1 (en) TNFSF-L Fusion Proteins and Uses Thereof
JP6018079B2 (ja) 非天然micタンパク質
JP2025509352A5 (cg-RX-API-DMAC10.html)
CN103833856B (zh) 抑制taci‑baff复合物形成的融合蛋白及其制法和用途